Percentage change in triglyceride level following saroglitazar 4 mg treatment.

At week 12 saroglitazar treatment led to increase in the C-peptide (percentage change: 59.42, 95% CI: 48.78, 70.06) and fasting insulin levels (percentage change: 47.10; 95% CI: 38.63, 55.57) when compared with baseline; however, it was with in normal range. Remarkable increase was observed in HOMA of beta cell function for C-peptide (percent change: 71.67; 95% CI: 39.09, 104.26) and HOMA of insulin resistance for C-peptide (percent change: 58.29, 95% CI: 46.74, 69.83) at week 12 from baseline.